SCHEMBL25817589

C=C(C)C1CC[C@]2(C(=O)O[C@H]3C[C@@H](O)[C@H](O)[C@@H](CCO[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@H](O)[C@H]4O)O3)CC[C@]3(C)[C@H](CCC4[C@@]5(C)CC[C@H](O[C@@H]6OC[C@H](O)[C@H](O)[C@H]6O[C@@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O)[C@@](C)(CO)[C@@H]5CC[C@]43C)[C@H]12

nearest known ligand 0.81

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	PC	P11498	7/20	0.81

▸	F3	P13726	3/20	0.56

▸	XDH	P47989	3/20	0.46

▸	USP2	O75604	1/20	0.46

▸	LMNA	P02545	1/20	0.46

▸	TP53	P04637	1/20	0.46

▸	MAPK1	P28482	1/20	0.46

▸	PTGS1	P23219	2/20	0.43

▸	PTGS2	P35354	2/20	0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30543004	0.89	PC (1.00)	PCF3XDHPTGS1PTGS2
SCHEMBL25993869	0.89	PC (1.00)	PCF3XDHPTGS1PTGS2
SCHEMBL22567668	0.89	PC (1.00)	PCF3XDHPTGS1PTGS2
SCHEMBL23983781	0.89	PC (1.00)	PCF3XDHPTGS1PTGS2
SCHEMBL25817580	0.89	PC (1.00)	PCF3XDHPTGS1PTGS2
SCHEMBL23983782	0.89	PC (1.00)	PCF3XDHPTGS1PTGS2
SCHEMBL25817542	0.88	PC (0.95)	PCF3XDHPTGS1PTGS2
SCHEMBL22145063	0.86	PC (0.73)	PCF3XDHPTGS1PTGS2
SCHEMBL31256542	0.85	PC (0.92)	PCF3XDHPTGS1PTGS2
SCHEMBL24486419	0.84	PC (0.88)	PCF3XDHPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230201230-A1	APPLICATION OF ANEMOSIDE B4 IN PREPARATION OF A DRUG FOR TREATMENT OR PREVENTION OF PSORIASIS	Guangxi Xinhai Pharmaceutical Technology Co., Ltd. (CN)	2023-06-29	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230201230-A1	APPLICATION OF ANEMOSIDE B4 IN PREPARATION OF A DRUG FOR TREATMENT OR PREVENTION OF PSORIASIS	IL17A, IL4, TNF	PC 2926/4885F3 878/4885XDH 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.